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ABSTRACT 
 
Addictive disorders/substance use disorders (SUDS) affect almost everyone in the United 
States, either directly or indirectly.  The cost of substance abuse to the social and economic 
structure in the United States is huge.  Anxiety is one of the most frequently mentioned 
symptoms which lead to relapse during the early weeks of recovery due to neurohormonal 
changes in the limbic system as well as cortisol production which occur during this time.  Present 
research in the treatment of anxiety in substance abuse and long term recovery is focused on 
genetics and pharmaceuticals, however most pharmaceuticals produce sedation.  Additional 
therapies in early recovery, which decrease the symptoms of anxiety while enhancing cognitive 
ability to learn and apply coping skills, are needed. 
Purpose: The purpose of this dissertation was to identify the natural degradation of anxiety 
symptoms occurring during the first few weeks following detox from alcohol or opiates.  To 
identify non pharmacological methods in use to decrease anxiety symptoms during this period, 
and then examine whether treatment with Cranial Electrotherapy Stimulation (CES) would 
enhance the degradation of anxiety symptoms.  
Methods and Results: The initial prospective study of 53 men in residential treatment, measured 
anxiety on entry, 30 and 60 days. The results found that increased anxiety measured prior to a 
participant leaving against medical advice was more significant than increased anxiety measured 
on admission. The follow-on pilot study in the same residential program was a double-blind 
experimental study using CES with active and placebo CES units loaned from the manufacturer. 
The intervention was conducted during the first 3 weeks of opiate/alcohol abstinence; a period 
identified when anxiety peaks, and dropout rate is high. There were 29 men in the experimental 
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group and 31 in the placebo group.  Salivary cortisol and state anxiety were measured on the first 
and final day of CES treatment.  Anxiety was also measured at study enrollment and at 30 days 
when study enrollment was terminated.  The results were statistically inconclusive as both the 
placebo and CES (experimental) groups trended downward; however the trend was greater in the 
CES group.  
Discussion/Implications: Anxiety was identified as a significant factor in leaving treatment 
early.  Cranial Electrotherapy Stimulation appears to decrease anxiety in non-substance abusing 
populations.  However, these finding were not supported in this substance abusing population 
during the first month of recovery.  Although CES appeared to be the most promising alternative 
therapy, more research is needed in the use of this and other emerging therapies for the treatment 
of anxiety symptoms during this early recovery period. 
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CHAPTER 1: INTRODUCTION 
 
Addictive disorders/substance use disorders (SUDS) affect almost everyone in the United 
States, either directly through a family member, or indirectly through friends or acquaintances.  
The cost of substance abuse to the social and economic structure in the United States is huge. 
Indeed, more than $.5 trillion is spent annually in healthcare, and associated crime or accidents 
(National Institute of Drug Abuse [NIDA], 2012).  The personal cost to individuals is enormous, 
ultimately affecting all dimensions of functioning, including poor health (Curtis, Zahs, & 
Kovacs, 2013), poor interpersonal relationships, job losses, difficulty in school, as well as 
financial or legal problems (Harris, Smock, & Tabor Wilkes, 2011). Entering and maintaining 
recovery is a personal and ongoing struggle for most substance abusers. The treatment of 
substance abuse is complex and long term with no single effective treatment modality and 
involves collaboration between medical, psychiatric and social services. 
The focus of this dissertation is gaining a better understanding of anxiety symptoms in the 
first few weeks following substance withdrawal in patients suffering from alcohol and opiate 
dependence. The aim of this research is to identify whether complementary and alternative 
therapies and cranial electrotherapy stimulation (CES) in particular, has a role in the treatment of 
anxiety symptoms during this period of early drug abuse recovery.  
Addiction is a brain disease, which has been aptly described by Nora Volkow, Director of 
NIDA, as ‘’the brain being hijacked’’ (Volkow, 2014).  Youthful experimentation or adult 
substance use to deal with stress, anxiety or pain (both emotional and physical) may lead to 
physical and psychological dependence.  The trajectory from use to abuse, and ultimate 
dependence on one or more drugs, is due to a variety of physiological factors which are 
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influenced by the individual’s genetic makeup and by life experiences which lead to changes in 
the gene alleles (epigenetic changes).  Most individuals never become physically or 
psychologically dependent.  However in those that are affected, the dependence may happen 
with the first use, or develop slowly over a number of years.  Most do not recognize their drug 
dependence as a problem until it starts to affect personal, social, work and family relationships.  
What is initially seen as a solution to life stressors ultimately becomes the stressor itself. 
The Stages of Change Model as described by Prochaska and DiClemente (1984) has become 
the working model for identifying substance abuse and starting treatment for the substance 
abuser.  Motivational interviewing is used to move an individual from pre-contemplation to 
contemplating change in the substance abuse behavior.  However, once the individual has made a 
decision to change, and moves from the preparation phase into the action phase, multiple 
obstacles line his path.  Not all individuals need a medical detox but for those who do, protocols 
and treatment are available and easily implemented.  The hard work starts after this, with the 
development of post-acute withdrawal symptoms which may be both physical and emotional.  
This is early recovery.  Anxiety is one of the most frequently mentioned symptoms which lead to 
relapse during the early weeks of recovery (Levy, 2008) and is thought to be exacerbated by the 
disequilibrium of dopamine and endogenous opioids within the limbic system (Sher, 2002) as 
well as changes in the production of cortisol (Lovallo, 2006). 
There is no single overarching theory which binds all the components of substance abuse. 
Many theories have been developed by individuals (or scientists) within the healthcare 
disciplines involved in the care and treatment of substance abusers.  However, the Theory of 
Allostasis is broad enough to address the biopsychosocial dimensions of this multifaceted 
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disorder.   Allostasis is conceptualized as a process that allows for ongoing evaluation and 
neurochemical adjustments between internal and external psychological demands on the 
individual (Ganzel, Morris, & Wethington, 2010).  Allostasis is a central nervous system driven 
response which integrates appraisal, coping, learning and memory into the physiological 
response to these demands.  Cortisol is produced when allostasis is not achieved and is a 
response to fear. 
 In the substance abuser, allostatic accommodation occurs initially within the neural 
circuitry of the limbic system in response to the drug of abuse, creating a drug dependent state of 
allostasis.  When the drug of abuse is withdrawn, allostasis is lost and there is a further 
dysregulation of cortisol production (Koob, 2003) and therefore increased symptoms of anxiety.   
Present research in the treatment of anxiety in substance abuse and long term recovery is 
focused on genetics and pharmaceuticals.  The goals of most research are to reverse epigenetic 
changes associated with continued substance abuse, block negative memories and fully map the 
relationships of drugs to the limbic system (Nestler, 2014).  
Group and individual psychotherapy has been the mainstay of substance abuse recovery for 
many years.  Epigenetic changes occurring during psychotherapy are well documented (Feinstein 
& Church, 2010).  Pharmacological agents presently used to attenuate symptoms of anxiety 
during withdrawal often have side effects which limit the efficacy of treatment, and in the 
recovery period, often are not used long term due to cost and limited effectiveness.  Treatment 
with somatic and complementary methods (CAM) has been used in an adjunct capacity for many 
years in substance abuse and offers potential long term options.  
4 
 The current state of the science of non-pharmacological therapies used for the treatment of 
the symptoms associated with anxiety during substance abuse withdrawal is discussed in Chapter 
2 of this dissertation.  Specifically discussed are somatic and complementary therapies (CAM) as 
used in the various Stages of Change Model (Prochaska &  DiClemente,1984) within the 
continuum of substance abuse treatment.  These therapies include acupuncture, massage therapy, 
meditation, yoga and music.  Also identified are somatic therapies involving electrical and 
magnetic stimulation of neurons in the limbic system which have emerged as potential 
treatments for substance use disorders and the associated negative symptoms such as anxiety. 
These modalities include deep brain stimulation, transcranial magnetic stimulation, direct current 
stimulation and cranial electrotherapy stimulation (CES).  Case studies with good results using 
these modalities have provided the impetus for further research into their effects on substance 
abuse and associated anxiety symptoms.  However, the research is not broad with a limited 
number of studies completed.   
In chapter 4 of this dissertation a study completed prior to the CES study discussed in 
Chapter 3, is presented.  The use of present ‘standard of care’ treatment and subsequent changes 
in anxiety was examined during a single group repeated measures study of anxiety during the 
first two months of substance abuse treatment of men in the same treatment facility.  Results in 
this study identified that anxiety is a significant factor in relapse during the first two months of 
treatment and that individuals with persistent anxiety were less likely to complete treatment than 
those whose anxiety remitted during the first few weeks after detox.   
Decreasing the anxiety associated with post-acute withdrawal, is one of the components 
critical to insuring that patients continue on the recovery path. In Chapter 3, a Randomized 
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Controlled Trial (RCT) using CES conducted during the second to fourth weeks following detox 
is reported.  This research was conducted with a group of 56 men in a residential treatment 
facility that had recently completed a medical detox from either alcohol or opiates.  Anxiety and 
cortisol responses were measured during the treatment phase. Cranial electrotherapy stimulation 
(CES) is a somatic treatment that has been used for many years in the treatment of generalized 
anxiety and was identified as a modality which could be easily used in a recovery program with 
minimal training of both staff and patients.  No recent studies have been reported on its use in 
decreasing anxiety in early substance abuse recovery.  Although CES may be effective in 
reducing anxiety and cortisol response in this population, it was not demonstrated in this study. 
Psychopharmacological medications as well as placebo effect may have confounded the results. 
The research results in this dissertation have extended the knowledge of the effect of anxiety 
symptoms on treatment dropout.  This research also identified an alternative therapy in CES 
which may be effective in decreasing anxiety in early recovery in specific substance abusing 
populations. However further research is needed in the use of CES to identify whether higher 
anxiety at intake and earlier use of CES in opiate abusers would cause greater symptom 
attenuation.  Recommendations regarding focus of treatment for anxiety were made based on the 
results of these studies and are being implemented in the residential facility where the research 
was conducted.  
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CHAPTER 2: THE ROLE OF COMPLEMENTARY AND ALTERNATIVE THERAPIES 
IN SUBSTANCE ABUSE RECOVERY: A STATE OF THE SCIENCE PAPER 
 
 
Psychotherapy and 12 step programs have been the cornerstone for substance abuse 
treatment for the last 75 years.  Since the 1960s, substance abuse has slowly moved from being 
viewed as a moral failing to being recognized as a disease with a physiologic basis.  As such, 
research in treatment has gradually moved the treatment focus to pharmacological solutions.  
Although progress is being made in identifying pharmacologic treatments for detox and 
recovery, attaining and sustaining recovery from substances of abuse remains a challenge, with 
many persons relapsing within 2 weeks of detoxification (Chutuape, Jasinski, Fingerhood, & 
Stitzer, 2001) and less than 50% remaining in recovery at 6 months (Gil-Rivas, Prause, &  
Grella, 2009). In fact, little improvement has been noted since the 1980s in achieving sustained 
recovery (Dennis, Foss & Scott 2007).   
During these and subsequent years, there has been a renewed interest in all alternative and 
complimentary modalities as potential tools for decreasing symptoms associated with substance 
withdrawal, as well as increasing time in recovery.  Acupuncture, massage therapy, yoga, 
meditation, exercise and music are often integrated into substance abuse treatment.  Other 
emerging modalities involving somatic interventions include Transracial Magnetic Stimulation 
(rTMS), Deep Brain Stimulation (DBS), Direct Current Stimulation (DCS), and Cranial 
Electrotherapy Stimulation (CES).  These are presently used to treat mood disorders and may 
also have a role in substance abuse treatment.  The purpose of this state of the science paper is to 
explore the current research and use of complementary and alternative therapies (CAM) as well 
9 
as other non-pharmacological somatic modalities which may have a role in decreasing anxiety in 
substance abuse recovery treatment.  
Scope of the Problem 
Long term recovery from substance abuse is often an elusive goal for many people.  The 
cost of abuse, detox, recovery and relapse is a financial burden to our society ((National Institute 
of Drug Abuse [NIDA], 2012) as well as to families and individuals struggling with substance 
abuse. 
The burden of substance abuse often starts with youthful experimentation, early addiction 
and often accidental death.  Substance abuse often stems from traumatic childhood experiences 
and mental health disorders, precipitated by genetic vulnerability (McQuown &.Wood, 2010). 
This vulnerability may be either enhanced by nature (genetic) or nurture (epigenetic) as has been 
described by social and biological scientists (Feinstein & Church, 2010; Nestler, 2014). This 
genetic effect continues into adulthood and often into the work environment.  It is manifested by 
the negative consequences related to substance abuse which may include poor health, poor 
interpersonal relationships, job losses, difficulty in school, and financial or legal problems 
(Harris, Smock, & Tabor-Wilkes, 2011).  Most individuals with substance use disorders 
experience some of these problems during their time in active addiction. 
Adults in the prime of life often use opiates to cope with chronic pain. Alcohol and 
cannabis have been used for millennia to cope with stress and anxiety.  Many persons become 
marginalized in our society as the substance of abuse affects their social and work lives (Darke, 
2012).  Substance abuse is a complex issue.  The genetic influence of substance abuse extends 
far beyond the direct effect of the drug on the affected neurotransmitter and the up or down 
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regulation at the neuronal synapses (Solinas, Thiriet, Chauvet, & Jaber, 2010).  Epigenetic 
changes associated with alcohol abuse are implicated in the attenuated immune response as is 
found in chronic inflammation and delayed response to infection.  This is manifested in higher 
rates of pneumonia, hepatitis C progression and liver cancer, as well as affecting the health of 
many other organ systems within the body. (Curtis, Zahs, & Kovacs, 2013). 
Not even our elderly are spared the effects of substance abuse, struggles with recovery and 
subsequent relapse. Alcohol abuse has long been recognized as increasing with aging and at 
retirement (CSAT, TIP #26, 1998). It is often in this later phase of life that alcohol abuse is 
identified by family members as being problematic, interfering with social and family life. 
Opiate use for non-medical and non-cancerous pain also increases in older adults (NSDUH, 
2009). The elderly with substance use disorders are also more likely to have co-morbid 
psychiatric conditions and generally be in poorer health (Taylor & Grossberg, 2012).  
Present Best Practices 
The most successful model for substance abuse recovery in the past 75 years has been 
Alcoholics Anonymous (AA), or some variation of the 12 step program (Kaskutas, 2009).  Used 
in many recovery programs as well as in the community, AA is useful for many substance 
abusers and is widely accessible (Miller, Sorensen, Selzer, &  Brigham, 2006).  However, it is 
not an effective model for all people as long-term recovery remains elusive for many (Dennis et 
al., 2007).  Other individual and group psychotherapy treatments are also effective in decreasing 
the incidence of relapse (Finnerty, 2012), especially when used in conjunction with 
pharmacological treatment. 
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Medical management tends to be short-term and often not sustainable due to cost and 
intensity of management both by participants and the health care system.  This is evidenced by 
the high percentage of individuals who cycle through substance abuse treatment and mental 
health facilities on a continual basis (Finnerty, 2012).  Long term medical (pharmaceutical) 
management of substance abuse is limited to opiate replacement therapies such as methadone or 
buprenorphine maintenance.   Many people also cycle in and out of these highly intensive and 
costly programs.  The use of disulfiram, acamprosate and naltrexone in alcohol recovery is often 
limited to weeks or months (Seneviratne, & Johnson, 2015), and without supportive care has 
very little impact on length of recovery. 
Over the past 2 decades, addiction research has focused on both neurochemicals and 
genetics.  The role of genetics and the hypothetical ability for the reversal of epigenetic changes 
has become a primary focus for further research in sustaining substance abuse recovery (Nestler, 
2014).  The other focus at present is through pharmacological advances.  However, counseling 
and behavioral change strategies also have a known long term impact on sustained recovery and 
gene reversal (Carroll & Rounsaville, 2007; Feinstein & Church, 2010).  The emerging 
modalities involving the somatic interventions of Transcranial Magnetic Stimulation (rTMS), 
Deep Brain Stimulation (DBS), Direct Current Stimulation (DCS), and Cranial Electrotherapy 
Stimulation (CES), are presently used to treat mood disorders (Rosa & Lisanby, 2012), and may 
also have a role in substance abuse treatment.  Other Complementary and Alternative Medicine 
(CAM) somatic therapies also have an adjunct role in substance abuse recovery.   
A literature search was conducted using EBSCO and PSYCINFO. Only articles written in 
English were reviewed and were limited to studies published since 1980.  Key words included 
12 
substance abuse, anxiety and each of the identified treatment modalities. One thousand and nine 
abstracts were reviewed and the results of thirty studies were included in this review.  This 
review includes seminal studies when identified and systematic reviews when available. Studies 
with similar methods and outcomes were not included (See Table 1).  
 
Table 1: Measures and results for CAM studies 
Reference Population 
Sample 
Size Study Type 
Length of 
study Measures Outcome 
       
Acupuncture       
       
Alster 2010 recovery 
program 
100 Qualitative 1 year:  3-6 
treatments 
Interview 
post 
treatment 
Improved 
anxiety 
Bergdahl et al 2014 Residential early 
treatment 
15 Qualitative Unknown Post 
treatment 
interview 
Decrease in 
anxiety 
during 
treatment 
Bearn et al 2009 During opiate 
detox 
83 RCT (2 groups) 
acupuncture and 
TAU control 
14 days SOWS No 
difference 
between 
groups 
Black et al 2011 Early 
withdrawal 
101 RCT (3 groups) 
Acupuncture, 
sham and 
relaxation 
 
3 
treatments 
over 2 
weeks 
STAI Decrease in 
anxiety in all 
groups 
Chang et al 2014 Veterans in 
recovery 
67 RCT (3 groups) 
Acupuncture , 
relaxation and 
TAU 
10 weeks 
2 
acupuncture 
sessions 
weekly 
STAI Decreased 
anxiety in 
both 
treatment 
groups 
       
Massage, 
meditation and 
Yoga/mindfulness 
 
   
 
 
   
       
Alterman  et al 
2004 
Recovery 
program 
31 Qualitative 
(Mindfulness) 
5 months Pre post 
test 
ASI 
 
 
 
No better 
than TAU 
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Reference Population 
Sample 
Size Study Type 
Length of 
study Measures Outcome 
       
Black et al  2010 Recovery 
program 
40 RCT (2-groups) 
Chair massage 
and relaxation 
3 days STAI State anxiety 
sustained for 
24 hours in 
CM group 
Chang et al 2014 Veterans in 
recovery 
67 RCT (3-groups) 
(relaxation, 
acupuncture and 
TAU 
10 weeks 
45 mins per 
week of 
relaxation 
therapy 
STAI Decreased 
anxiety after 
2 weeks in 
treatment 
groups 
Chen et al 2010 Substance abuse 
recovery 
248 RCT  (2 group 
)meditation/yoga 
vs relaxation 
2 weeks STAI Decreased 
anxiety after 
2 weeks both 
groups 
Ospina et al 2008 All CAM in 
recovery 
 Systematic 
review 
400 RCTs 
various various Studies 
generally 
weak 
Reader et al 2005 Alcohol 
withdrawal 
50 RCT (2 group) 
Massage therapy 
and TAU 
1
st
 4 days of 
Alcohol 
withdrawal 
AWS Decreased 
pulse after 
15 minutes 
Khanna et al 2013 Preparation 
Phase for 
Substance abuse 
treatment 
 Qualitative 
review 
Various Various Improvement 
in stress 
symptoms. 
Decrease in 
sympathetic 
activity 
Smith et al 2011 Community 
Volunteers 
50 RCT (2 group) 
Mindfulness 
Stress reduction 
and Cognitive 
Behavioral Stress 
Reduction 
8 weeks Perceived 
Stress 
Scale – 
pre and 
post tx 
MBSR p< 
0.000 and 
CBSR p 
<0.013 
Music Therapy       
       
Bonny 1986 Substance abuse unknown Qualitative   Evokes 
emotions and 
physiological 
response 
Chaieb et al 2015 Various 30 
articles 
Qualitative 
review (binaural 
beats) 
various various Modulating 
mood states 
with regular 
sessions 
Mays et al 2008 Substance abuse 
treatment 
unknown Qualitative 
review 
Of 5 studies 
Adjunctive 
therapy 
interview Felt was 
“helpful” 
       
Trans cranial 
Magnetic 
Stimulation 
      
       
14 
Reference Population 
Sample 
Size Study Type 
Length of 
study Measures Outcome 
       
Gorelick et al 2014 Substance abuse 
treatment 
316 Systematic 
review 19 studies 
DLPFC per 
protocol 
Interview, 
VAS 
May be 
promising to 
decrease 
craving 
Grall-Bronec et al 
2014 
Substance abuse 
treatment 
 Systematic 
review 18 studies 
DLPFC per 
protocol 
VAS 11 studies 
supported 
decreased 
craving 
Mishra et al 2010 Alcohol 
dependence 
45 RCT  Single 
blind with 
placebo group 
R DLPFC 
per protocol 
10 sessions 
ACQ-
NOW, pre 
post and 1 
month 
Measured 
craving only 
Significant 
decrease 
Mishra et al 2015 Alcohol 
dependence 
40 RCT  double 
blind  to R and L 
DLPFC 
Per 
protocol 10 
sessions 
ACQ-
NOW 
Same time 
points 
No 
difference 
between 
groups. 
Craving 
decrease 
significant 
Jansen et al 2013 Substance abuse. 
Active users 
 Systematic 
review 
9 RCTs. Placebo 
controlled. 3 with 
Alcohol 
Various R 
or L 
DLPRC 
Various Decrease 
craving for 
alcohol in 
active group 
       
Transcranial 
Direct Current 
Stimulation 
      
       
Jansen et al 2013 Substance 
abusers 
 Systematic 
review 8 RCTs 
TMS with DCS 
Various Various Decrease 
craving in 
both groups 
       
Cranial 
Electrotherapy 
Stimulation 
      
       
Bystritsky et al 
2008 
Generalized 
anxiety in 
outpatient 
12 Open label 6 weeks HAM-A 50% with 
decrease in 
anxiety 
Barclay et al 
2014 
Anxiety in 
Primary care 
115 RCT double 
blinded 
5 weeks HAM-A 85% with 
decrease in 
anxiety 
       
Reference Population 
Sample 
Size Study Type 
Length of 
study Measures Outcome 
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Kirsh et al 2007 Substance 
abusers 
335 Meta analysis 
15 studies 
various various Decrease in 
anxiety 
Krupitsky et al 
1991 
Alcohol 
withdrawal 
20 RCT  STAI Robust 
Decrease in 
anxiety 
Overcash et al 
1989 
THC 
withdrawal 
32 Open label   Robust 
decrease in 
anxiety 
Rose et al 2009 Caregivers of 
Alzheimers 
patients 
42 RCT Double 
blind 
30 days Ham-A No change 
in 
symptoms 
Schmitt et al 
1986 
Polysubstance 
abuse in 
treatment 
60 RCT double 
blind 
 STAI Robust 
decrease in 
anxiety 
Winick 1999 Dental office 
During 
procedure 
33 RCT Double 
blind – placebo 
and CES 
Single 
treatment 
VAS at 3 
time 
points 
Significant 
decrease in 
anxiety 
       
 
 
Complementary and Alternative Medicine  
Acupuncture 
Acupuncture has been used as a modality for the treatment of multiple conditions in China 
for several thousand years (Myatt, 2005).  It is believed that endogenous opioids play a role in 
acupuncture analgesia and are released during acupuncture.  Acupuncture is also thought to 
stimulate the hypothalamus and pituitary, resulting in a broad spectrum of neurotransmitter and 
neurohormone release; most importantly, the endogenous opioids and subsequent cascade to 
release of ACTH and then cortisol release (Lui, Li, Xia, & Terplan, 2009).  This is conceptually 
similar to the gate theory of pain which was first described by Melzack and Wall (1965).  The 
NIH Consensus Statement on Acupuncture (1997) advised that “there is sufficient evidence of 
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acupuncture’s value to expand its use into conventional medicine and to encourage further 
studies of its physiology and clinical value” (Conclusion section, para. 5).  
The NIH Consensus Statement (1997) also discussed multiple other factors that make 
research studies on the use of acupuncture difficult as many other factors may profoundly affect 
the therapeutic outcome.  These variables are described as the relationship between the patient 
and the clinician, the amount of trust developed in the relationship, the expectations of both the 
patient and the clinician, as well as the belief systems of both individuals.  These variables set 
the tone for the therapeutic relationship and contribute to the outcome of the (acupuncture) 
treatment (NIH, 1997).  These same psychosocial parameters which affect treatment outcomes in 
acupuncture also affect outcomes in substance abuse treatment.  Indeed, acupuncture has been 
used successfully in substance abuse treatment for more than 35 years (Cai-Lian, Liu-Zhen, & 
Fei, 2008). This is consistent with the NIH Consensus Statement (1997). 
Most recent studies have focused on auricular acupuncture using a protocol developed by 
the National Acupuncture Detoxification Association (NADA).  This protocol, using 5 needles 
placed at specific points in the ear auricle, is thought to improve retention in treatment by 
decreasing drug cravings, anxiety and lessening physical symptoms of withdrawal (Carter & 
Olshan-Perlmutter, 2014).  However, research regarding the use of auricular acupuncture in 
substance abuse treatment, remains limited without clear outcomes in many studies. 
Chang and Sommers (2014) reported on a study where auricular acupuncture was compared 
to relaxation response in a 10 week study on reducing craving and anxiety in veterans recovering 
from substance abuse.  Results indicated substantial decreases in anxiety and craving following 
an individual session of acupuncture (p <.001) or relaxation response (p<.03), with craving 
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continuing to drop with continued sessions.  However, it was not determined whether it was the 
regular attendance or daily practice of relaxation response techniques that elicited the change 
(Chang & Sommers, 2014). Similar concerns have been voiced by other researchers (Alster, 
2010; Bergdahl, Berman, & Haglund, 2014).  
In another recent Randomized Controlled Study (RCT) of 101 patients in substance abuse 
treatment (Black, Carey, Webber, Neish, & Gilbert, 2011), the hypothesis that auricular 
acupuncture would be effective in reducing anxiety was not supported. Anxiety was measured 
using a pre and post-test design.  Participants were randomized into 3 groups: active auricular 
acupuncture using the NADA protocol, sham acupuncture, and relaxation therapy.  Each 
received 3 treatments over 2 weeks.  There was a significant drop in state anxiety in all treatment 
groups (p<.001) immediately following each treatment but there was no difference between each 
of the groups.  
When auricular acupuncture was used during a 14 day opiate detox using methadone, 
auricular acupuncture was not found to decrease opiate withdrawal symptoms in a study of 83 
participants (Bearn et al., 2009).  In this RCT, participants were randomized into control and 
acupuncture groups.  Demographics in both groups were statistically similar.  There were no 
significant differences in the severity of withdrawal symptoms between the 2 groups. 
An observational study on the use of auricular acupuncture in a residential treatment 
program was described by Martin Alster (2010).  In this setting, auricular acupuncture, using the 
NADA model was implemented 1-3 times weekly along with mindfulness meditation.  Most 
clients received 3-6 treatments.  Non-specific benefits included feelings of contentment and 
relaxation.  More specific improvements in symptoms included better sleep, reduced cravings 
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and anxiety as well as general improvement of mood.  Negative reports voiced by participants 
were occasional feelings of lightheadedness or burning at the needle site.  The staff were 
concerned that the treatment was time-consuming and labor-intensive.  The staff also observed 
that the group dynamic was a factor in both the participants’ willingness to participate or, in 
some cases, their refusal to do so. 
In another qualitative study (Bergdahl et al., 2014) similar findings of increased relaxation, 
feelings of well-being, peacefulness and harmony, as well as decreased anxiety and drug use 
with auricular acupuncture were reported.  Concerns voiced by the participants were that the 
process was time consuming, the effect was short-term, there was dependence on someone else 
to give the treatment, and that cravings remained after treatment termination. 
Massage, Meditation and Yoga 
Many other modalities involving relaxation have been used to decrease the anxiety and 
stress symptoms associated with substance use withdrawal.  Studies generally report 
improvement of symptoms but difficulties identifying appropriate control groups continue to 
plague these studies.  
A study of chair massage (N=40) over 3 days was compared to relaxation therapy (N=42) as 
the control condition (Black et al., 2010).  Participants were recovering from alcohol, cocaine or 
opiate withdrawal.  Anxiety was measured using the Speilberger State /Trait Anxiety Inventory 
(STAI).  Anxiety was reduced in both groups but to a greater extent in the Chair Massage (CM) 
group (state, p= 0.001 and trait p=0.045).  The state anxiety decrease was sustained for over 24 
hours in CM, but not in the relaxation therapy control group.  Standard counseling and 
pharmacological management were also included.  Standardized procedures were used for each 
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group to include the same time each day, same length of time, same room, same physical lighting 
and the same staff member in the room.  There was no physical contact with the participants. 
Content validity and internal consistency of STAI (r=0.83) as well as benchmark for anxiety 
were addressed.  Heart rate response demonstrated no significant difference. An incidental 
finding of a mean downward trend in diastolic blood pressure was observed in both groups 
(p>.0001).  This may have been related to a physiological response to decreased anxiety but was 
not addressed by the author. 
Another study of massage therapy identified a reduction in anxiety and also in heart rate 
(Reader, Young, & Connor, 2005).  This study of patients during the first four days of alcohol 
withdrawal identified a decrease in pulse rate of 3-4 beats per minute after 15 minutes of upper 
body massage.  The control group was treatment as usual.  However there was no comment on 
how long the lower pulse rate lasted.  The confounder of increased attention to the participants 
could have affected the results (Reader et al., 2005). 
Meditation has also been extensively used in substance abuse treatment.  A study using 
qigong meditation (QM) was compared to stress management and relaxation training (Chen, 
Comerford, Shinnick, & Ziedonis, 2010).  Chen et al. (2010) described QM as an interaction of a 
variety of Chinese exercises and therapies, described as integrating body, breath and mind into 
‘oneness’.  Yoga and transcendental meditation are considered forms of QM.  The process 
includes slow abdominal breathing, inward attention, guided imagery and focus on maintaining 
an ‘empty mind’.  Participants in both groups followed recorded instructions.  This study showed 
no significant difference in state anxiety between the stress management and relaxation training 
group and the QM group.  Both groups noted decreased anxiety at the end of two weeks.  The 
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expected decrease in anxiety over time was not addressed.  Individuals with low group 
participation had more anxiety at the end of week two than participants who regularly attended 
either of the two treatment groups.  The participants also discussed the barriers they identified to 
completing the meditation program.  Comments included “too much for me”, “too much on my 
mind”, “cannot concentrate”, “not sure how it can help”, “should not occur during free time”.  
Many participants would have liked to have had the yoga integrated with regular activities, not as 
an additional activity. There was no discussion on increased time in recovery.  
Mindfulness meditation has also been studied in substance abuse recovery (Alterman, 
Koppenhaver, Mulholland, Ladden, & Baime, 2004).  In this study, meditation did not affect the 
results of the Addiction Severity Index (ASI) when measured over 5 months during the patients’ 
stay in residential treatment for substance abuse. (N=31).  With mindfulness meditation, 
breathing is used as the focus of attention for meditation.  Emphasis is placed on paying attention 
to restlessness and irritability, then attempting to calm physiological responses of the body and 
calm the mind. In this population, extra attention was placed on managing impulsivity and its 
relationship to substance abuse.  There was no evidence that this training had better outcomes 
than treatment as usual.  However, the authors commented that this treatment might be more 
helpful in specific populations such as those with higher interest in religiosity or spirituality. 
The relationship of spirituality to the effects of mindfulness and yoga was described by 
Khanna and Greeson (2013).  Their review of complementary treatments in substance abuse 
found support for the use of yoga in conjunction with mindfulness in treatment.  This 
combination of therapies appeared to enhance recovery from addictive disorders, by targeting 
stress-related cognitions, emotions, and drug craving.  There was also evidence that when yoga 
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and meditation targeted individuals with high spirituality there was a significant decrease in 
cortisol production (31%) after each session that was not found in those who used yoga for 
physical exercise only (Smith, Greer, Sheets, & Watson, 2011).  Yoga was often referenced as an 
adjunct activity available in recovery programs and also in therapy sessions for individuals still 
in the preparation phase of substance abuse recovery (Chen et al., 2010, Khanna & Greeson, 
2013).  Unfortunately, no RCTs specifically involving yoga were found related to substance 
abuse recovery treatment. 
Ospina et al. (2008) completed a systematic review of meditation clinical trials between 
1956 and 2005 including mindfulness, yoga, T’ai chi and QM.  Issues with many studies 
included publication bias, empirical evidence varying between the quality of the study and the 
effect of treatment, self-selection into groups, motivation to participate as well as difficulty in 
blinding both the control and experimental groups.   The authors felt there were threats to 
validity at all levels despite statistically significant improvements in many studies (Ospina et al., 
2008).   
Music Therapy 
Music has been used as an adjunct therapy in substance abuse treatment for many years. 
A systematic review by Mays, Clark, and Gordon (2008) identified music as an adjunct therapy 
in 5 studies with participants generally feeling that music was ‘helpful’. Reports were qualitative 
and no RCTs were available.  Bonny in her seminal writing in 1986 identified music as a non-
verbal therapy which activated emotions and a physiological response, produced symbolic 
images and enhanced the other senses. However, only 14% of substance abuse treatment 
programs offer music therapy (Aletraris, Paino, Edmond, Roman, & Bride, 2014).  More recently 
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there has been renewed interest in the concept of binaural beats imbedded in music having an 
effect on mood.  In this systematic review (Chaieb, Wilpert, Reber, & Fell, 2015) there was some 
evidence of decreases in both state and trait anxiety with regular sessions, however no RCTs 
have been published related to substance abuse recovery.  The authors mentioned that further 
research was needed to identify neural mechanisms as well as sound ranges most likely to be 
effective (Chaieb et al., 2015).  
Other Somatic Treatments 
During the past decade there has been renewed interest in the use of modulating 
neurohormones through the use of electrophysiology.  Manipulating behavior and cognition 
through the use of electrical currents has been used for over 70 years, primarily as 
Electroconvulsive Therapy (ECT) for the treatment of severe depression.  There was some 
interest in the effect of ECT on substance abuse in the 1990s.  However, individual positive case 
studies (Pearlman & Savanin, 1999) did not lead to RCTs indicating effectiveness on a broader 
scope (Moss, & Vaidya, 2014).  More positive results have been identified using other 
modalities. 
Deep Brain Stimulation 
Deep Brain Stimulation (DBS), a neurosurgical procedure involving the placement of 
directed electrodes within the brain, has been developed to treat movement disorders such as 
Parkinson’s disease and other neurological conditions associated with severe tremor.  The 
electrical stimulus appears to interact with the corticostriatal circuits and associated neurons (also 
highly implicated in substance abuse) but the exact mechanism of action is unknown (Soyka & 
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Mutschler, 2015).  Pierce & Vassoler (2013) theorized that targeting the nucleus accumbens and 
sub thalamic nucleus may hold promise for an effect on substance abuse.   Although individual 
reports and case studies have been reported in which an effect on substance abuse was found, 
completing an RCT has proven difficult as patients are reluctant to enroll for this invasive 
procedure (Luigjes, Brink, Schuurman, Kuhn, & Denys, 2015).  More research studies are 
available using non-invasive technologies. 
Transcranial Magnetic Stimulation 
About 20 years ago Trans-cranial Magnetic (TMS) therapy was introduced and studied for 
the treatment of depression and other neurocognitive disorders.  It is presently FDA approved for 
use in resistant depression.  Repetitive (r) TMS is based on the theory that a magnetic field 
passing through the cranium, induces an electrical field that can alter neuronal activity.  The 
primary target for rTMS in the treatment of substance uses disorders is the dorsolateral prefrontal 
cortex (DLPFC) (Gorelick, Zangen, & George, 2014).  The DLPFC assists in the regulation of 
the limbic system through its involvement in higher-order executive functions such as self-
control and being aware of behaviors and related events which are intimately involved in 
substance abuse (Goldstein & Volkow, 2011).  Interest in rTMS in substance abuse occurred 
after the publication of case studies of patients exposed to this therapy for depression who noted 
improvement in their craving symptoms.  This has led to further research studies.  
Jansen et al. (2013), in a meta- analysis, reviewed 9 sham controlled studies involving 
substance abuse.  Three studies involved alcohol use and identified an effect on craving 
reduction (p = .06).  There were no differences in craving reduction across other substances:  
nicotine, and food.  These studies involved active substance abuse rather than individuals in 
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recovery.  In another literature review, Grall-Bronnec, and Sauvaget (2014), identified 18 studies 
using rTMS to treat substance abuse.  Eleven studies supported the efficacy of rTMS in the 
reduction in craving which was usually measured using a visual analog scale (VAS). However, 
these effects were short-term which was thought to limit the effectiveness of the treatment.  A 
small RCT identified a decrease in alcohol craving in a single blind, sham controlled study of 45 
patients with alcohol dependence (Mishra, Nizamie, Das, & Praharaj, 2010).  Thirty patients 
were in the active group. High-frequency rTMS to the right DLPFC was used for a total of 10 
sessions.  Alcohol craving, using the Alcohol Craving Questionnaire (ACQ-NOW) was 
measured at base line, after the last rTMS session and 1 month later.  Effect size for treatment 
with time was moderate (r = 0.401).  Decrease in craving at 30 days was significant (p<0.0005). 
This study was criticized due to concerns regarding placebo effect, the use of rTMS only on the 
right DLPFC as well as limiting measurement to subjective identification of craving (Trafton, 
2010).  
 A subsequent study was conducted by Mishra, Praharaj, Katshu, Sarkar,  and Nizamie, 
(2015) in an attempt to decrease this criticism.  This study was double blinded using 20 patients 
with alcohol dependence syndrome randomly assigned to receive rTMS over either the right or 
left DLPFC, using the same settings as in the previous study.  Measurement was the ACQ-NOW 
at the same time points.  The results showed no difference between groups and time but did 
identify significant reduction in craving scores in both groups over time (p < 0.0001).  
 Use of rTMS in substance abuse recovery shows promise.  However the limitations with 
the present studies include no references to, or identification of, long term recovery or use of 
repeated treatments over extended periods. Transcranial magnetic stimulation appears to be a 
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safe modality based on use for psychiatric disorders but more research is needed before moving 
this modality into substance abuse treatment. 
Transcranial Direct Current Stimulation 
Transcranial direct current stimulation (tDCS) is a recent addition to the 
electrophysiological tool box of substance abuse treatment modalities.  This method (tDCS) was 
initially researched in the 1960’s; however no significant results were published.  Little research 
was reported until the past decade when results of research involving rTMS stimulated renewed 
interest in tDCS.  Direct current stimulation is applied using a simple devise, obtainable on the 
internet and charged with a 9 volt battery.  This devise provides a very low direct current (1-2 
mA) in a single direction from the anode to the cathode attached to the cranium with saline 
moistened sponges and a strap (Rosa, & Lisanby, 2012).  The focus of current research is also on 
applying the current to the DLPFC and the subsequent effect on cognition, mood and behavior.  
Few research studies using tDCS relating to substance abuse and craving are available. 
Jansen et al (2013), in a meta-analysis of 8 studies of tDCS compared results of rTMS to 
tDCS, and found comparable decreases in alcohol craving (z = 5.832, p < 0.001).  These devices 
are not FDA approved for any specific disorder, however, they are available without a 
prescription from multiple internet sources.  They are advertised as providing low level electrical 
current to the brain for various neurocognitive problems. 
 
 
Cranial Electrotherapy Stimulation (CES)  
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Cranial Electrotherapy Stimulation  was developed in the Soviet Union in the 1950s and has 
been used in the United States since the 1960s, initially as a treatment method called ‘electro 
sleep’.  Low level (100 to 600 microamps) micro current is given to the patient through 
electrodes placed on the earlobes for a varying amount of time (Kirsh & Smith, 2000).  The 
device is presently used in the Veterans Administration System (Tan, Dao, Smith, Robinson, & 
Jensen, 2010) and by psychologists in general practice for the ancillary treatment of pain, 
anxiety, depression and insomnia, (Kirsh, & Gilula, 2007).  Research protocols in a variety of 
patient conditions have varied from a single treatment, a one hour treatment weekly to 20-30 
minute sessions daily over several weeks.  Initial CES studies focused on anxiety in a substance 
abusing population were conducted 20 years ago (Schmitt, Capo & Boyd, 1986; Overcash & 
Siebenthall, 1989; Krupitsky et al.,1991).  Results in all these studies were described as 
statistically significant, although only Krupitsky et al. (1991) identified a p value (p<.05). No 
negative side effects were identified.  However, no recent studies have been conducted to 
evaluate relief of anxiety in substance abuse withdrawal.  
The use of CES in Generalized Anxiety Disorder has also been studied (Bystritsky, 
Kerwin, & Feusner, 2008).  In a small open label study (N = 12), participants ranging in age 
from 29-58 years were recruited from the community.  All received an active CES unit. There 
was no control group. CES was administered for 6 weeks using a 0.5-Hz frequency and a 300-u1 
A intensity.  Both the Hamilton rating Scale for Anxiety (HAM-A) and the Clinical Global 
Impressions-Improvement scale (CGI-I) were used to measure anxiety pre- and post-treatment. 
Fifty percent (6 patients) had a 50% decrease in the HAM-A (p = .01) and a rating of 1 or 2 on 
the CGI-I (much improved, or very much improved).  An additional patient had significant 
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improvement in anxiety score but did not meet criteria for the study standard.  Adverse events 
mentioned were mild headache or nausea.  A limitation of the study mentioned by the authors 
was the small sample size and that it was open label, which may have impacted on the results. 
A similar study by Barclay and Barclay (2014) evaluated CES in a group of primary care 
patients (n=115) with anxiety disorders.  In this double blinded study, participants were recruited 
from the community and paid $30 to enroll in the 5 week study.  Individuals in the placebo group 
were given an opportunity to use the active unit following their completion in the study.  In this 
study, 85% of the participants in the active CES group had an overall reduction in anxiety at 
study termination.  The average reduction was 32% from anxiety baseline as measured with the 
HAM-A (F=43.401, df =1 p=.001, d=.94).  
Other researchers have also reported positive study results using CES.  A double blinded 
study using CES to decrease anxiety during dental procedures is often referenced (Winick,1999).  
In this study (N=33), 17 patients were randomized to the experimental group using CES at 0.5 
Hz and a sub sensory A setting of 200-u1, while the 16 patients in the placebo group had sham 
CES units.  The manufacturer did not release the codes for active or placebo units until after the 
study was completed.  Measurement was a 7 point Likert scale which rated the degree of 
improvement of anxiety at completion of the procedure and a Visual Analog Scale (VAS) 
measuring anxiety from ‘not anxious’ to ‘very anxious’.  The measurements were taken at 3 time 
points during the procedure: prior to initiation, midway, and at completion. Both the dentist and 
the patient completed both ratings at each time period.  (The dentist rated his perception of the 
patient’s anxiety).  Results of the VAS for both patient and dentist observer indicated decreased 
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anxiety in experimental group when compared to the placebo group (p < .02) and this was 
corroborated with the Likert results ( p < .01) (Winick,1999). 
Another double blind study examined the effect of CES on sleep and depressive symptoms 
in 42 care givers of patients with Alzheimer’s disease.  This study found no statistically 
significant differences between the placebo and experimental groups (Rose, Taylor, & 
Bourguignon, 2009), although there was trending towards significance on the sleep index.  The 
authors felt that a limitation was that the study was underpowered.   
Empirically, CES appears to assist in bringing neurotransmitters back into homeostasis.  
However, the exact mechanism of action remains unclear.  This effect is thought to be due to the 
effect on the parasympathetic nervous system through stimulation of the auricular branch of the 
vagus nerve (Kirsh & Gilula, 2007).  By changing the electrical and chemical activity in the 
brainstem, CES appears to amplify activity in some neurological systems and diminish activity in 
others.  Critique of many studies included low power due to few participants, methodological 
differences and difficulty controlling for multiple variables (Bystritsky et al., 2008; Rose et al., 
2009). Although CES has been studied in patients with various anxiety related disorders, and 
appears to be effective, no recent studies have focused on anxiety in the period of early substance 
abuse recovery.   
Summary 
The heterogeneity of substance abuse and its effect on individuals is a conundrum for 
researchers.  The thread throughout these presented studies is that RCTs are difficult to conduct 
due to the multiple variables associated with individuals in recovery for substance abuse.  
Demographics may be similar, as may be the substance of abuse, but each individual comes with 
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his or her own genetic makeup and unique epigenetic changes.  Although RCTs remain the gold 
standard for research, they are challenging to complete or reproduce in substance abuse treatment 
due to multiple variables associated with small treatment populations in individual recovery 
programs.  This heterogeneity of substance use disorders with the widely differing individual 
responses to treatment portend a need for individually developed treatment plans.   As research 
moves into practice, it is critical that all potential modalities which may enhance epigenetic 
reversal, and improve the sustainability of substance abuse recovery be assessed for use in each 
individual.  Most but not all of these complementary modalities have been found to decrease 
either anxiety or craving in specific individuals with substance use disorders.  Cranial 
electrotherapy stimulation is a modality that seems especially promising since it does not require 
individual monitoring or specialized group attendance, and if effective may be used by 
individuals on an ongoing basis.  The effect of CES on decreasing anxiety in non-substance 
abusing populations appears to be robust.  This effect may also be apparent in substance abusing 
populations. However previous studies in early substance abuse recovery are limited and have 
not been replicated in many years.  Research in all these modalities should be continued, and 
when found effective, be implemented into practice for developing individual integrated care 
models needed for enhancing and sustaining recovery in each substance abuser. 
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CHAPTER 3: THE EFFECT OF CRANIAL ELECTROTHERAPY STIMULATION AS 
A METHOD TO DECREASE ANXIETY SYMPTOMS FOLLOWING OPIATE AND 
ALCOHOL WITHDRAWAL 
 
Abstract 
Background: Almost 35% of men suffering from alcohol or opiate dependence drop out prior to 
completing residential programs of 30 days or less.  Anxiety is often a quoted reason for early 
dropout.  Supplemental interventions designed to promote tenure in residential treatment are 
sorely needed for men who are substance abusers.   
Purpose:  The purpose of this study was to determine if Cranial Electrotherapy Stimulation 
(CES), which is FDA approved for the treatment of anxiety and depression, would decrease 
anxiety in substance abusing men in early recovery. 
Methods:  A double blind experimental study using repeated measures and two treatment 
conditions (intervention/active and control/placebo) was conducted over a period of 15 days 
during the first 3 weeks of opiate/alcohol abstinence.  Salivary Cortisol and state anxiety were 
measured on the first and final day of CES treatment.  Anxiety was also measured on all 
participants at study enrollment and at 30 days.  
Results:  Fifty nine participants completed the study. Anxiety and cortisol responses improved in 
both groups.  While differences were not significant, the cortisol decrease was greater in the 
active treatment group than in the placebo group.  In addition there appeared to be a trending 
downward in momentary anxiety as measured in the active group.  
Conclusions: CES may be effective in reducing anxiety and cortisol response in this population; 
however it was not demonstrated statistically in this study.  Psychopharmacological medications 
as well as placebo effect may have confounded the results.  More research is needed in this area. 
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Introduction 
Substance abuse is an individual and public health problem that costs the United States 
more than $0.5 trillion annually in health care, lost earnings, and associated crime or accidents 
(National Institute of Drug Abuse [NIDA], 2012).  A majority of substance abusers are men. 
Indeed, over one quarter of the 8.5 million men arrested in 2010, were arrested for charges 
relating directly to substance abuse (Bureau of Justice Statistics, 2012).  Approximately 1 million 
people access residential substance use treatment each year.  Of these, two-thirds are men, many 
of whom are referred directly from the Criminal Justice system (Substance Abuse and Mental 
Health Services Administration [SAMHSA], 2012).  
Men are more likely to abuse opiates and alcohol than women (SAMHSA, 2012) and 
they also start substance abuse at a younger age than women.  However, they enter treatment 
later, making them at greater risk for poorer treatment outcomes, having less family support and 
greater involvement with criminal activity (Grella & Joshi, 1999).  Almost 35% drop out prior to 
completing residential programs of 30 days or less (SAMHSA Office of Applied Studies, 2009). 
Hence, supplemental interventions designed to promote tenure in residential treatment are sorely 
needed for men who are substance abusers.  The purpose of this study was to investigate whether 
Cranial Electrotherapy Stimulation (CES) would decrease anxiety symptoms and increase 
retention in treatment. 
Background 
Anxiety is the most common and disabling of the acute withdrawal symptoms 
(McGuinness & Fogger, 2006) and has been identified as a significant reason for treatment 
dropout and subsequent relapse (Levy, 2008).  Anxiety generally peaks within two weeks of 
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substance abstinence (Ganzel, Morris & Wethington, 2010; Sher, 2002), but may persist for 
many months. Anxiety also affects individuals’ ability to learn and complete the cognitive tasks 
needed to successfully complete residential treatment (Burriss, Ayers, Ginsberg, & Powell, 
2008).  
Anxiety symptoms are a product of continued sympathetic stimulation (Koob, 2005).  In 
the substance abuser, this occurs when the hypothalamic-pituitary-adrenal (HPA) axis is 
stimulated by the neurohormones which are dysregulated during withdrawal of the substance of 
abuse (Lovallo, 2006).  Various medications are presently used to attenuate the anxiety 
symptoms associated with this dysregulation in an effort to enhance program participation and 
continuation in treatment.  The most effective medications for relief of anxiety are the 
benzodiazepines.  However, medications in this class are not appropriate for use in a substance 
abusing population as these medications, which have a high addictive potential, may create 
further addictive behavior in these individuals (Casher, Gih, & Bess, 2011). 
   Other pharmaceutical agents approved for anxiety relief such as buspirone, hydroxyzine, 
trazodone and doxepin have limited efficacy (Casher, Gih & Bess, 2011).  In addition the 
antihistamine and anticholinergic side effects of dry mouth and sleepiness may make them less 
tolerable. Many other medications administered to treat anxiety are used “off label” and include 
atypical antipsychotic and antiepileptic drugs (McGuinness & Fogger, 2006; Pollack et al., 
2008).  Antipsychotic and antiepileptic medications decrease negative emotions, and also 
attenuate cognitive processing and produce daytime sedation (Gilula & Kirsch, 2005).  These 
unwelcome side effects limit the cognitive resources available for developing anxiety 
management skills. 
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Providing recovering addicts with anxiety management skills during the early post-acute 
withdrawal period is critical to sustaining recovery (Gil-Rivas, Prause,& Grella, 2009; Gossop, 
Stewart, Browne, & Marsden, 2002).  As substance-abuse treatment for men focuses on group 
therapy and psychoeducation, participants need to be able to concentrate in order to participate 
fully in treatment offered to acquire these skills.  This underscores the need for new, non-
pharmacological approaches to manage anxiety during the acute withdrawal period that occurs 
early in the recovery process.   
Cranial electrotherapy stimulation (CES) is a non-pharmacological approach to anxiety 
management that may have promise to improve retention in residential treatment and decrease 
early relapse.   CES was developed in the Soviet Union in the 1950s, and first used in the United 
States in the 1960s to treat insomnia via a method then referred to as electro sleep (Kirsh & 
Smith, 2000).  The technique was later approved by the U.S. Food and Drug Administration 
(FDA) (2011) for use in the treatment of anxiety as well as depression and sleep disorders.  CES 
is presently used in the Veterans Administration System (Tan, Dao, Smith, Robinson, & Jensen, 
2010), as well as in general practice for adjunctive treatment of anxiety, depression, and 
insomnia.  
It (CES) is believed to reduce anxiety symptoms through pulsed alpha wave alternating 
current which affects neurotransmitters in the limbic system and subsequent downstream 
engagement of the parasympathetic nervous system (Giordano, 2006; Gunther & Phillips, 2010).  
This alpha wave stimulation ultimately results in decreased (more normalized) cortisol 
production (Bystritsky, Kerwin, & Feusner, 2008; Kirsh & Gilula, 2007).   
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  The beneficial effect of alpha wave stimulation on cortisol regulation may be particularly 
promising for individuals in substance abuse treatment as sustained elevations of cortisol are 
known to occur during this time (Li et al. 2008; Lovallo, Dickensheets, Myers, Thomas, & 
Nixon, 2000; Sinha et al. 2011).  A blunted cortisol response (cortisol levels not quickly 
returning to pre-stress baseline) to short stressful situations has also been identified in alcoholics 
and polysubstance abusers (Daughters, Lejuez, Kahler, Strong, & Brown, 2005; Lovallo et al., 
2000).  In addition, Daughters et al. (2005) noted that substance abusers were more likely to drop 
out of residential treatment if cortisol did not return to the expected baseline after completing a 
stressful task.  
To date, no studies have addressed whether a more normalized (less blunted) cortisol 
response occurs in early recovery when an individual is treated with a single episode of CES.  
Nor have studies addressed whether a CES related change in the cortisol response is associated 
with a momentary reduction in anxiety (i.e: state anxiety), or whether repeated use is associated 
with a reduction in anxiety lasting a few days. 
 A Meta-analysis of 15 CES treatment studies (n=335) published by Kirsh and Gilula, 
(2007) provides evidence of a therapeutic effect in decreasing anxiety and other somatic 
symptoms (r = .65+8) among a variety of substance-abusing populations being treated in various 
settings.  CES treatment was found to be effective for relieving anxiety in a non-substance 
abusing population with hour long treatments over several weeks (Bystritsky, Kerwin, & 
Feusner, 2008, Barclay & Barclay, 2014).  A positive effect was also identified during a single 
treatment for state anxiety exacerbated by dental procedures (Winick, 2009).  This suggests that 
(1) a single treatment of one hour may decrease cortisol level as well as state anxiety, and (2) 
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multiple treatments over several weeks may be effective in decreasing anxiety in substance 
abusers during the time in residential treatment. 
Purpose  
The purpose of this study was to determine if Cranial Electrotherapy Stimulation (CES), 
which is FDA approved for the treatment of anxiety, depression and insomnia, would decrease 
anxiety in substance abusing men in early recovery.  Decreased anxiety in residential treatment 
has been identified as a factor associated with remaining in residential treatment (Hutchison, 
2016. Chapter 4).  
Method 
Design 
A double blind experimental study using repeated measures and two treatment conditions 
(intervention/active and control/placebo) was conducted over a period of 15 days during the first 
3 weeks of opiate/alcohol abstinence.  Anxiety and PTSD symptoms were measured at study 
enrollment.  Anxiety and depression symptoms were measured at 30 days (study completion). 
Study AIMS 
 AIM 1: to compare in men in early substance recovery treatment for substance abuse the 
effects of Cranial Electrotherapy Stimulation or placebo on anxiety and depression.  
 AIM 2: to compare in men in early substance recovery treatment for substance abuse the 
effects of Cranial Electrotherapy Stimulation or placebo on cortisol level. 
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Setting and Sample 
The setting for this study was a Level II residential treatment program for men which is 
operated by the Center for Drug Free Living (CFDFL) and certified by the Commission on 
Accreditation of Rehabilitation Facilities.  Only the Level II program clients residing on campus 
were eligible for study enrollment.  A level II program was selected as this provides up to 6 
hours of psychosocial support daily in a structured environment.  The treatment program 
includes daily group sessions with psychoeducation, as well as weekly individual counseling.  In 
this environment, participants could be monitored for compliance with the treatment protocol.   
Participants were initially recruited during their stay in the medical detox facility when 
the PI discussed the study during the weekly community meeting.  All clients completing an 
alcohol or opiate medical detox were eligible to participate if they met the administrative criteria 
for admission into the Level II residential treatment program and intended to stay in treatment 
for at least 30 days.  Individuals with mental health disorders were not excluded if they were 
considered appropriate for residential treatment.  Exclusion criteria were: (1) having an 
implantable electrical device (this exclusion criterion was recommended by the CES 
manufacturer); (2) unable to read or understand English; (3) recent dental surgery or bleeding 
oral lesions (blood in the salivary cortisol specimen affects accuracy of measurement).  Four to 
six individuals who met the study criteria were typically admitted every week.  Approximately 
five months were required to enroll 79 study participants.  
Study Measures 
A demographic questionnaire was used to assess age, education, race/ethnicity, housing 
situation prior to admission, primary substance of abuse and mental health disorders prior to 
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admission.  Additional variables included chronic medications and previous residential treatment 
admissions.  Symptoms of PTSD and depression were also collected as independent variables. 
 The PTSD Checklist—Civilian Version (PCL-C) was used to assess for symptoms of 
posttraumatic stress disorder (PTSD) which clients were presently experiencing Mental Illness 
(Research, Education and Clinical Centers [MIRECC]. n.d.).  This self-administered instrument 
has been in general use for more than 20 years in both military and civilian populations (Orsillo, 
2001).  Scores of less than 29 are considered not significant for PTSD, while those above 45 are 
considered of high enough severity for continuing with the assessment for the diagnosis of 
PTSD.  The PCL consists of 17 items identified with the diagnosis of PTSD in the DSM, and 
uses a 5 point Likert scale.  Internal consistency is high (r = .75) across studies in various 
populations (Wilkins, Lang, & Norman, 2011). 
 Anxiety experienced since leaving the detox facility was measured using the Zung SAS 
(Zung, 1971).  This self-administered anxiety scale is used for identifying anxiety symptoms that 
have occurred within the past few days.  The Zung is a 20 item measure of somatic and 
psychological symptoms reflecting on feelings over the identified time frame.  Each item is 
scored using a 4 point Likert scale with 5 items being reverse scored.  Anxiety scores between 45 
and 60 are considered moderate anxiety, and scores between 60 and 74 are considered severe 
anxiety.  A raw score of > 36 is clinically significant for difficulty carrying out normal work or 
activities (Zung, 1980).  The Zung has good reliability (r = .71, alpha = .798; Zung, 1971) and 
content validity when compared to the Hamilton Anxiety scale (r =.75) (Sharpley & Christie, 
2007).  The Zung scale has been used in various populations for research and clinical assessment 
since its development in 1971 (Sharpley & Christie, 2007).  
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 Depression was measured at 30 days in recovery treatment using the Patient Health 
Questionnaire (PHQ-9).  This depression scale was originally developed by Spitzer, Williams, 
and Kroenke (1999) with a grant from Pfizer Inc.  The PHQ-9 is a 9-item self-report measure 
that assesses the nine depression symptoms from the DSM-IV depression criteria (Kroenke et al., 
2001). Each item is scored on a 4-point scale (0–3) and scores range from 0 to 27.  Similar to the 
Beck Depression Inventory (BDI), the summed scores can be used to describe the patient’s 
symptoms in one of five interpretive categories: none (0–4), mild (5–9), moderate (10–14), 
moderately severe (15–19), and severe (20–27).  A cut-off score of > 10 is generally used to 
identify individuals likely to have major depressive disorders (Kroenke, et al., 2001).  The PHQ-
9 has been shown to be highly correlated (r =0.76) with the Beck Depression Inventory and has 
good internal consistency (r =.87) when used in residential substance abuse treatment (Hepner, 
Hunter, Edelen, Zhou & Watkins, 2009). 
  State anxiety was measured using the 6 item State-Trait Anxiety Inventory (STAI-6; 
Marteau & Bekker, 1992).  The STAI-6 is a self-administered measure of state anxiety.  This 6-
item version of the Speilberger STAI (Tiuczek, Henriques, & Brown, 2009) correlates well with 
the full (20 item state anxiety) STAI (r=.95) and has good internal consistency (alpha = .82) as 
well as excellent construct validity in clinical populations (Court, Greenland, & Margrain, 2010).  
 Cortisol was collected using a commercially prepared self-collection kit designed to 
measure salivary cortisol and was provided by Salimetrics (Salmetrics 2011), the laboratory 
chosen to evaluate the cortisol levels.  This laboratory provided support for collection and 
shipment, in addition to performing salivary cortisol assays (Salimetrics, 2012).  The average 
morning cortisol level reported by Salmetrics (2012)  for adult males between ages 31 and 50 is 
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0.122 - 1.551.  Salimetrics uses a duplicate sample of saliva and a highly sensitive immunoassay 
which has a lower limit of sensitivity of 0.003ug/dl and a standard curve ranging from 
0.012ug/dl to 3.0 ug/dl.  The average intra-assay coefficient has a variation of 3.5% and inter-
assay coefficient of variation of 5%.  Serum and saliva samples show strong linear relationship (r 
= .91, p < 0.0001) which is consistent with McCracken & Poland’s (1989) work indicating a 
strong connection between salivary and circulating cortisol (r = .78, p < .03) when both are 
measured over time within the same individual. 
Procedure 
Each participant had a uniquely numbered CES unit assigned to him on day 1 of the 
treatment period.  The unit was randomly pulled from the box of units by the PI when directions 
for use were being reviewed prior to the first treatment.  This unit was then labeled with his 
name.  Neither the participant nor the PI was aware of whether the unit was a placebo or active 
CES unit.  The participant picked up his unit each day, applied saline solution to the ear clips and 
attached them to his ear lobes.  He then turned on the unit as instructed and proceeded with 
normal activities until he returned it to the storage bin an hour later when the unit automatically 
turned off.  At that time he signed the log book to validate time and length of use.  The log book 
was checked daily by the PI or the facility nurse to insure compliance with instructions.  
 The three week CES treatment period began during the first week following the medical 
detox and continued for a total of 15 daily one hour sessions over the following three weeks.  If 
participants were unable to complete the number of treatments within this time frame they were 
withdrawn from the study. 
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Data Collection Procedures 
Salivary Cortisol was collected on the first and final day of CES treatment, before and 
after the daily CES treatment session scheduled for that day for all participants.  Cortisol was 
measured between 0815 and 0845 am and again between 0930 and 1000 am following 
completion of the hour long treatment on these days.  As morning cortisol levels usually peak 
within 2 hours of arising and then gradually decrease during the day, collection at these time 
points allowed for consistency between participants.  State anxiety, using the STAI 6 was 
collected at these same 4 time points.  
Anxiety symptoms experienced during the past few days were measured using the Zung 
SAS on all participants at study enrollment and at 30 days.  PTSD symptoms, using the PCL-C, 
were measured on admission.  Depression, using the PHQ-9, was measured at 30 days as 
recommended in the literature (Hepner et al. 2009).  
Each participant received a gift card to a big-box retail store (Walmart) at two time 
points: Completion of the second salivary cortisol and STAI-6 on the day one (first) treatment 
session ($5), and after completion of the Zung SAS, and the PHQ-9 on day 30 of residential 
treatment ($10). 
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Figure 1: Flow of Participants through the study 
Recruitment of potential participants at 
the Detox facility (n=79 males) 
 
Excluded if not meeting 
inclusion criteria 
Admission to residential Program 
 After completion of Zung SAS and PHQ-9 on day 30, the participant’s 
participation in the study was terminated and he was given a final gift card. 
Continue daily treatment intervention with CES device for 15 treatments within 21 days.  Repeat Salivary Cortisol and   
STAI-6 pre and post final CES treatment session. 
Enrollment and collection of baseline data: Consent,   
Demographics, PCL,   Zung SAS,   
On Day 1 of Treatment (day 2-4 after admission) 
Participants randomly assigned a CES unit which was 
either active or placebo, blinded to both the 
participant and the PI 
 
      
       
On day 30 of Residential Program - retake the Zung SAS (#2)  and PHQ -
9 completed.  $10 Gift Card given to Participant 
Study Termination 
Collection of Salivary Cortisol  and 
STAI 6 (pre- treatment) at  9 am 
Collection of Salivary Cortisol and 
STAI -6 (post-treatment) at 1030 am.  
($5 gift card given to participant) 
 One hour of treatment with double 
blinded CES device 
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Data Analysis 
Descriptive statistics (e.g., mean, standard deviation, frequency, and percentage) were 
calculated for all demographic variables to summarize sample characteristics and properties of 
the key study variables, including the proportion of participants with and without PTSD and/or 
depression in each study condition.  Differences in the demographic characteristics of the 
placebo and experimental group were investigated with Chi-square analysis for categorical data 
and t tests for continuous variables.  An alpha level of 0.05 was used in these analyses and in 
those used to address study hypotheses and research questions. 
Ethical Considerations 
This study was approved through the University of Central Florida Institutional Review 
Board.  Participation in the study was voluntary and not a requisite for enrolling in residential 
treatment.  There were no significant adverse effects identified during the use of this CES device 
during this study.  
Results 
 A convenience sample of 79 adult male participants who met study criteria were 
recruited for the study between October 2013 and April 2014.  Approximately 110 individuals 
were admitted into the residential treatment program for treatment of alcohol or opiate 
dependence following inpatient detox during the study period; 81 volunteered for entry into the 
study.  Two individuals were subsequently withdrawn by the investigator due to severe medical 
problems during the first few days in treatment.  The remaining 79 were randomized into either 
the control/placebo or experimental group. 
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Of the 79 randomized participants, 19 subsequently dropped out of the study.  One 
participant asked to be withdrawn and eventually finished residential treatment.  One participant 
was withdrawn by the PI as he was unable to complete all requirements within the study time 
constraints, and eventually dropped out of treatment.  The remaining 17 participants either left 
the program, or were terminated by the administration due to drug use (relapse) in the facility. 
Sixty participants completed the required number of CES treatments and 57 completed the 30 
day post treatment psychological inventories.  The attrition rate was approximately 24%, 
resulting in a sample for analysis of 57.  Assuming a power of .80 and an alpha of .05, a sample 
of 56 was estimated to be sufficient to detect a moderate (0.25) effect.  
Sample Characteristics 
There were no significant differences on the pretreatment demographic variables between 
the active and the placebo group of study completers.  Table 1 provides demographic data by 
treatment group.  The average age in the intervention group was 39 and 41 for the placebo group. 
The majority of participants in both groups were European/White race, homeless, educated at the 
high school level or higher and their primary substance of abuse were opiates.  
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Table 2: Population demographics of study completers 
     Variable                                                      Intervention n=29 Placebo 
n=31 
p value 
for Χ2 
Total 
n=60 
 n(%) n(%)  n(%) 
 
Age groups         p =.40  
    Less than 30 6 (10%) 10 (16.6%)  16 (26.6%) 
    31-50 15 (25%) 13 (21.6%)  28 (46.6%) 
    Over 50 8 (13.3%) 8 (13.3%)  16 (26.6%) 
         
Race/Ethnicity    p =.80  
    European/White 21 (35%) 20 (33.3%)  41 (68.3%) 
    Hispanic 5(8.3%) 8 (13.3%)  13 (21.6%) 
    African American 3 (5.0%) 3 (5.0%)  6 (10.6%) 
     
Living situation prior to treatment   p=.15  
    Family or self 6(10.0%) 6(10.0%)  12 (20%) 
    Living with parents 0 (0.0 %) 5 (8.3%)  5 (8.3%) 
    Transitional housing or friends 5(8.3%) 6 (10.0%)  11 (18.3%) 
    Homeless 18 (30.0%) 14 (23.3%)  32 (53.3%) 
     
Years of Education    p=.62  
    < High School 4(6.6%) 7 (11.6%)  11 (18.3%) 
    GED 9 (15.0%) 6 (10.0%)  15 (25.0%) 
    HS Diploma 7 (11.6%) 9 (15.0%)  16 (26.6%) 
college/trade/AA 9(15.0%) 9 (15.0%)  18 (30.0%) 
      
Primary Substances of Abuse   p=.98  
   Opiate   12 (20.0%) 12 (20%)  24 (40%) 
   Alcohol 9 (15.0%) 10 (16.6%)  19 (31.6%) 
    Poly substance with opiate  8 (13.3%) 9 (15%)  17 (28.3%) 
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The mean age of the dropout group was 35 compared to 41 in the completers.  All of the 
participants in the drop out group were opiate dependent while 32% of the study completers had 
a primary diagnosis of alcohol dependence. Opiate users are known to drop out earlier than 
alcohol users as their symptoms are often more severe and protracted.  Of interest is that 
completers endorsed more PTSD symptoms but less anxiety symptoms on admission and there 
was a difference between the STAI 1 and STAI 2 in these groups.  The other demographic 
markers of the participants were similar to that of the general population of clients admitted to 
this program.  Eleven of the 19 dropouts were in the active CES group.  
 
Primary Outcome Measures.   
The effect of CES treatment on generalized anxiety (Zung SAS), on state anxiety (STAI-
6), as well as on Depression (PHQ-9) was analyzed.  There were 31 participants in the placebo 
group and 29 in the experimental (active CES) group. 
  The participants had mean baseline Zung SAS scores of 43.55 (10.65) in the placebo 
group and 44.66(11.21) in the active CES group.  The Zung SAS at 30 days was 35.71 (10.6) in 
the placebo group and 36.90 (10.38) in the CES group.  Depression based on the PHQ-9 at 30 
days (Study termination) was 8.46(6.06) in the placebo group and 8.31(6.02) in the active CES 
group.  The number of participants on antidepressants at day 30 in the placebo group was 10 and 
15 in the active group.  Twelve of these participants were on antidepressants prior to starting 
treatment.  There were no significant differences between groups (see Table 2).  
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Table 3: Effect of CES on Anxiety and Depression 
 
 
The STAI-6 at baseline (prior to any CES treatment) was 12.94(3.97) in the placebo 
group and 13.90(4.40) in the active CES group.  Following the first CES treatment, the results 
were 11.73(3.95) in the placebo group and 13.10(4.12) in the active group respectively.  On the 
final day of CES treatment, the placebo group scored 11.51(4.26) and the active CES group 
scored 11.10(4.08) prior to the treatment session.  Following this final session the scores were 
11.38(4.51) and 10.38(3.56).  While these differences were not statistically significant at any 
time point, greater improvement was seen in the experimental group compared to the placebo 
group. 
Variable Placebo CES 
Mean and SD 
Active CES 
Mean and SD 
P value for 
Χ2 
    
Zung SAS  (Anxiety) on 
Admission 
43.58 (10.65) 44.66 (11.12) .19 
Zung SAS (anxiety) at 30 
days 
35.71 (10.60) 36.90 (10.38) .63 
    
Depression (PHQ-) at 30 
days 
8.46 (6.06) 8.31 (6.02) .12 
    
On antidepressants at  30 
days 
10 15 .15 
    
STAI 6 prior to 1st CES 
treatment 
12.94 (3.97) 13.90 (4.40) .47 
STAI 6 after 1st CES 
treatment 
11.73 (3.95) 13.01 (4.12) .67 
    
STAI 6 prior to last CES 
treatment 
11.51 (4.26) 11.10 (4.08) .73 
STAI 6 after last CES 
treatment 
11.38 (3.56 10.38 (3.56) .44 
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Secondary Outcome Measures. 
The effect of time and treatment on salivary cortisol levels was measured.  Cortisol was 
measured between 0815 and 0845 prior to CES treatment on the first and last day of CES use 
(both placebo and active CES group) and again between 0930 and 1000, following completion of 
the hour long treatment on these days.  Mean (SD) baseline salivary cortisol in the placebo group 
was .588 (.415) and decreased to .571 (.962) following the first treatment session.  In the active 
group the mean (SD) cortisol level was .386 (.287) prior to treatment, and decreased to .302 
(.254) following the initial session.  On the final day of CES treatment, the placebo group 
measured .328 (.208) prior to treatment and .201(.129) following the session.  The active CES 
group measured .340 (.193) and decreased to .168(.926) following the session (see Table 3).  
While these differences were not statistically significant, some interesting trends were noted. 
Salivary cortisol decreased in all of the participants following the initial session and continued to 
decrease until the completion of the program.  Importantly, while not statistically significant, the 
active CES group showed a greater downward trend in cortisol levels.  
 
Table 4: Effect of CES on Salivary Cortisol 
Cortisol  collection time Placebo 
Mean and SD 
Intervention 
Mean and SD 
P value of Χ2 
    
Cortisol before 1
st
 CES treatment .588 (.415) .386 (287) .40 
Cortisol after 1
st
 CES treatment .571 (.962) .302 (.254 .40 
    
Cortisol before last CES treatment .328 (.208) .340 (.193) .46 
Cortisol after last CES treatment .201 (.129) .168 (.926) .51 
    
 
Discussion 
57 
While this double blinded study identified no statistically significant differences in the 
response to anxiety between the experimental (CES) group and the placebo group at study 
conclusion, some important trends were noted.  The cortisol decrease was greater in the active 
treatment group than in the placebo group.  In addition there appeared to be a trending downward 
in momentary anxiety as measured by the STAI 6 in the active group at the end of the treatment 
phase.  These differences might have been more evident in a larger study group and/or in a group 
focused on a single chemical of abuse: either alcohol or opiate.  
The opiate dependent participants were generally younger and appeared to be less able to 
complete treatment as this was the only group who dropped out of the study.  However, there 
may be other, unidentified factors affecting the results.  All participants who completed the study 
were enthusiastic about participation and needed few reminders to come in and use the devices 
each day.   
Since participants did not know if they were receiving the CES or the placebo, many 
thought they were in the experimental group and felt less anxious.  There was also positive 
reinforcement within the study as each participant received increased social support due to 
multiple daily short interactions with the PI, her assistant or the facility nurse which could have 
influenced the outcomes.  If multiple arms had been used in this study such as a treatment, 
placebo and control group the results might have been statistically significant.  However, 
participants might have been more difficult to recruit into a control group (treatment as usual) if 
there was a perceived benefit to those in the active or placebo arms.  Also, the effect of increased 
social support from providers or the study team may have been a factor on the decrease in 
anxiety in both groups over the 30 day period.  The change in anxiety as manifested on the Zung 
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SAS was similar to that of a previous study in this population (Hutchison, 2016).  Also of 
interest, at 30 days in the program, neither group endorsed greater than mild depressive 
symptoms (PhQ-9 was less than 10).  However almost half the participants were on 
antidepressants:  more participants in the active treatment group were on antidepressants when 
compared to the placebo group.  The difference between groups was not significant as any of 
these participants were already on antidepressants when initially enrolled in the study.  Different 
results may have been obtained if none of the participants were on psychopharmacological 
medications. 
Implications  
The demographic differences between the dropouts and program completers are 
significant in that only opiate users  dropped out and were a few years younger (35 vs. 41) than 
those competing the study.  Opiate, alcohol and opiate/alcohol combined users behave differently 
and perhaps should be studied separately.  It may be important to recognize these differences, not 
only in research but also in treatment programs as the cultural and social differences in these 
populations may affect outcomes.  
Although the use of CES in this study did not show significant differences between the 
two groups in this study, the participants were engaged in an activity that they perceived to be of 
benefit.  More research is needed in this area.  In addition, using CES as an option for treatment 
in specific individuals who identify high anxiety symptoms on program arrival may affect their 
treatment outcome.  Individuals who have a preexisting diagnosis of generalized anxiety may 
also benefit from prolonged use.  There was considerable variation was noted between individual 
responses in this study.  An open label study might identify these individuals and their associated 
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individual characteristics.  More research is needed to identify these characteristics and 
relationship to CES use. 
Study Strengths and Limitations 
This was a small double blinded study at a single treatment program and study inclusion 
criteria were very broad.  However, because the participants were randomized to either 
intervention or control groups, the variability between and within groups should have been 
minimized.  An additional confounder was that the participants were treated with 
pharmaceuticals for anxiety, sleep and depression when indicated and this may have affected 
individual cortisol and CES response. 
Conclusion  
Although CES has been used for many years in the treatment of anxiety, in this study, the 
effect of CES was not significantly greater than that of the placebo in this population.  However, 
more research is needed in this area as the results may have been mitigated by the large number 
of variables.  Also, there was trending towards improvement of symptoms.  In future research, 
narrowing the criteria for study admission might decrease the number of variables.  Limiting the 
study to participants with a single substance of abuse and a high anxiety level on admission 
could provide a narrower focus on anxiety outcome.  An additional study measuring cortisol in a 
control group of substance abusing men awaiting residential placement and within a treatment as 
usual group of men in the residential recovery program, measured at the same time points as 
done in this study would be helpful.  This would determine if the gradual decrease in cortisol 
levels noted over time was an effect of the treatment/placebo or a normal effect of time in 
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substance abuse recovery or another unknown factor. A slow normalizing of cortisol response is 
expected.  Finally, in a future study, multiple arms in a trial, such as treatment, placebo and 
control group, might result in statistically significant outcomes.   
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CHAPTER 4: TRANSLATIONAL RESEARCH APPROACH FOR NURSE CLINICIANS 
EFFECT OF ANXIETY ON SUBSTANCE ABUSE TREATMENT AND EARLY 
RELAPSE IN RESIDENTIAL SUBSTANCE ABUSE TREATMENT 
 
 
Abstract 
Anxiety is a recognized, co-occurring disorder associated with substance abuse, and is a 
prominent negative emotion experienced by many patients during post-acute withdrawal from 
opiates and alcohol.  Although anxiety as a factor in relapse has been measured in longitudinal 
studies, little data exists on measuring anxiety during the first few weeks following medically 
assisted withdrawal, or how anxiety affects treatment and relapse during this critical time in 
residential treatment.  The aims of this study were to determine whether (1) patients who fail to 
complete residential treatment differ in level of anxiety symptoms on admission from those who 
complete treatment (2) patients who relapse, or leave residential treatment prior to completion, 
have higher anxiety scores prior to discharge than individuals who complete treatment, (3) self-
report of PTSD symptoms affects change in anxiety symptoms during the first 60 days of 
substance abuse recovery, and (4) reported PTSD is a significant factor in drop-out from 
residential treatment prior to completion. 
Methods: A prospective study was conducted with 53 males entering a residential program 
immediately following medical detox from alcohol or opiates.  A one group repeated measures 
design was used with anxiety data (Zung SAS) collected at entry, 30, and 60 days.  
Results: While the relationship between Zung anxiety scores on admission and leaving treatment 
were not significant (p-value =.96), there was a significant difference between the last measured 
anxiety score and leaving treatment prior to completion (p-value < .02) when compared to 
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treatment completers.  While not significant, there was a trend in the slowing of the rate of 
anxiety diminishing in those with PTSD symptoms and those without (p >.08).  However, men 
with PTSD did not leave treatment prior to completion more frequently than those without 
PTSD.   
Conclusion: Anxiety is a significant factor in relapse during the first two months of treatment. 
Individuals with persistent anxiety were less likely to complete treatment than those whose 
anxiety remitted during the first few weeks after detox.  Reported PTSD was not an independent 
risk factor in leaving treatment prior to completion. 
 
Introduction 
Empirical evidence suggests that most individuals will have significant anxiety during the 
initial weeks of treatment and early recovery from opiate and alcohol dependence (Schuckit & 
Hesselboch, 1994, Sher, 2002).  Stress and anxiety have been identified as high risk reasons for 
relapse (Levy, 2008).  Anxiety is a common co-occurring disorder in substance abusers (Smith & 
Book, 2008) and a multisystem response to a perceived threat or danger, generally produced by 
somatic symptoms in the present and cognitively by anticipation of stressful events in the future. 
It is the most prominent negative emotional state which many patients endure during the post-
acute withdrawal period immediately following medical detox (Colasanti, Rabiner, Lingford-
Hughes, & Nutt, 2010, McGuinness & Fogger, 2006).  
The anxiety symptoms commonly associated with substance abuse withdrawal during the 
first few weeks of abstinence are characterized by insomnia (Monti & Monti, 2000, Thakker 
20011), generalized irritability (Koob & Le Moal, 2005), low distress tolerance (Daughters, 
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,Lejuez, Kahler, Strong, &  Brown, 2005), difficulty with cognitive processing (Eysenck, 
Derakshan, Santos & Calvo 2007) and exacerbated by hypersensitivity to pain (Vachon-Presseau 
et al., 2013).  The amount and duration of these anxiety symptoms during this post-acute 
withdrawal period reflect a variety of neurochemical changes in the body, the extent of which are 
manifested by the individual’s personality, life experiences and genetic makeup (Nemeroff, 
1998), as well as the type and amount of preceding drug use.   
During the post-acute withdrawal period, many anxiety symptoms abate without 
treatment (DSM-5) over 3 to 6 weeks.  It is not known whether acute anxiety symptoms in the 
immediate post withdrawal period abate at a different rate in men who endorse symptoms of Post 
Traumatic Stress Disorder (PTSD) than in those who do not (Gil-Rivas, Prause, &  Grella, 2009). 
Nor have studies addressed whether a high level of anxiety during the first week following detox 
is a risk factor for relapse over the next two months.  However, it is known that the risk of 
relapse due to anxiety, when present, persists far beyond these first two months in recovery 
(Heilig, Elgi, Crabbe, &  Becker, 2010).  In a prospective study of substance abusers in recovery 
(Charney, Palacios-Boix, Negrete, Dobkin, & Gill, 2005), 48% presented with anxiety during the 
immediate post withdrawal period.  Of these, only 40% of them were abstinent at 6 months. This 
evidence suggests that increased anxiety at intake is a predictor of treatment outcome.  
The negative effect of lifetime trauma such as childhood abuse (Elliot et al., 2014) has 
also been identified as an increased risk factor associated with relapse and continued substance 
abuse (Lejuez et al., 2008, Darke, 2013).  In a convenience study of male substance abusers (Gil-
Rivas et al., 2009), 73% had a preexisting diagnosis of mood disorder, and 52% had a life time 
diagnosis of PTSD.  Almost 27% admitted to a lifetime history of opiate dependence and more 
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than 70% to alcohol dependence.  Anxiety was measured at three time points: within 48 hours of 
admission, at 3 months and at 12 months.  Anxiety was highly correlated between all the time 
points (r = .71, P < .001). Relapse rates of 45.3 % at 3 months and 52.6% at 12 months were 
identified in those with PTSD.  Anxiety symptoms did not decrease between 6 and 12 months 
after start of treatment.  
Effect of Treatment on Anxiety 
Relieving anxiety, and the commonly associated somatic symptoms, as well as 
addressing the psychosocial components of addiction, are paramount for maintaining patients in 
treatment and reducing dropout and relapse.  In early recovery, the inability to attend to what is 
being taught also increases the risk of relapse during this initial period because learning coping 
skills and increasing self-efficacy are critical components of recovery.  Anxiety has been shown 
to decrease attention and ability to successfully complete tasks.  Studies have confirmed this in 
alcoholics in early recovery (Daughters et al., 2005).  A study in college students (Chapell et al., 
2005) also identified that with increased anxiety, comprehension in learning new material 
decreases.  
A meta-analysis of anxiety and its relationship to performing creative tasks, suggested 
that there is a significant negative relationship between increase in anxiety and the ability to 
complete verbal tasks (p <.001) (Byron & Khazanchi, 2011).  When individuals devote more 
cognitive resources to their anxiety and its symptoms, less personal resources are available for 
creative expression.  Anxiety is also a component of low distress tolerance (Keough, Riccardi, 
Timpano, Mitchel, & Schmidt, 2010).  Daughters et al. (2005) addressed the impact of low 
distress tolerance in  substance abusers during early recovery (n = 89, 62% male, almost 90% 
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alcohol or poly substance abusers, 80% high school or less) in a period of 6 weeks of inpatient 
treatment.   A significant reduction in task completion was noted (r = .27), (p =.01) between 
those participants who were tested more closely to (1-2 weeks post) detox when compared to 
those who were tested 5 to 6 weeks post-detox.  
Anxiety in Integrative Treatment  
An integrative approach to substance abuse treatment which focuses on enhancing coping 
skills, relapse prevention, psycho-education and 12 step programs, as well as psychotherapy in 
individual sessions for both the substance abuse and concurrent mental health disorders has been 
supported for many years (Miller, Sorensen, Selzer, & Brigham, 2006).  Hesse  (2009)  in a 
systematic review focusing on anxiety and depression in substance use treatment, found some 
support for integrated psychotherapy in the treatment of depression and substance abuse. 
However, due to a paucity of similar studies, a meta-analysis was unable to be completed on 
anxiety during substance abuse recovery treatment.  Five studies were identified, which met 
criteria, but measurement methods were dissimilar.  In these studies there was little evidence to 
suggest that non-somatic or specialized treatment of anxiety disorders yielded any significant 
benefit during early recovery.  However, there was a recommendation that more research was 
needed in this area (Hesse, 2009).  Therefore, the purpose of this study was to identify the level 
of anxiety experienced by men in early recovery in an integrative substance abuse program. 
The aims of this study were to determine whether (1) patients who fail to complete 
residential treatment differ in level of anxiety symptoms on admission from those who complete 
treatment, (2) patients who relapse, or leave residential treatment prior to completion, have 
higher anxiety scores prior to discharge than individuals who complete treatment, (3) self-report 
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of PTSD symptoms affects change in anxiety symptoms during the first 60 days of substance 
abuse recovery, and (4) reported PTSD is a significant factor in drop-out from residential prior to 
treatment completion.   
Method 
Design 
This study used a one group repeated measures design with anxiety data collected at 
entry, 30 days, 60 days, and at discharge.  Symptoms of PTSD were measured at intake and 
correlated with anxiety measures at each time point. 
Setting 
The setting for this study was a Level II residential treatment program operated by the 
Center for Drug Free Living (CFDFL) and certified by the Commission on Accreditation of 
Rehabilitation Facilities.  This Level II program provided up to 6 hours of psychosocial support 
daily in a structured environment.  The treatment program included daily group sessions with 
psychoeducation, treatment with psychopharmaceuticals as needed, as well as weekly individual 
counseling.  This model of integrated treatment is the present standard of care for substance 
abuse treatment.  All residents admitted to the Level II program were referred directly from the 
associated detox facility.  The average length of stay in the program was 60 days but varied from 
30 to 90 days.   
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Enrollment and Duration of Study 
A total of 53 men who met study criteria of either opiate or alcohol dependence were 
enrolled over 12 weeks between 1 January 2012 and 5 May 2012. Each participant had 
completed either an opiate (63%, n = 33) or alcohol (37%, n = 20) medical detox in the week 
prior to admission.   
Required Sample Size 
Attrition rate was 26 % resulting in a sample of analysis of 39 at 30 days of treatment. 
Assuming a power of .80 and an alpha of .05, a sample of 39 was sufficient to detect a moderate 
effect.   
Procedures 
The study was discussed with all potential participants by the principal investigator (PI) 
at the Detox facility’s weekly community meeting.  Participants were recruited on arrival at the 
residential treatment facility and 53 participants were enrolled.  Within 48 hours of arrival at the 
program, the PI met with interested clients, obtained informed consent and gave the client a copy 
of the signed consent.  The participants then completed the entry demographic questionnaire and 
the PTSD Checklist –Civilian version (PCL-C).  Participants also completed the baseline anxiety 
(Zung SAS) inventory during a clinical interview with the PI on the same day study enrollment 
was completed.  On day 28-30 and on day 55-60 of the program, the participants completed the 
Zung SAS again if they were still enrolled in treatment.  Participants remaining in residential 
treatment also completed the final Zung SAS at 90 days (n = 3).  If participants did not wish to 
be contacted, or left without notice, this was noted on the discharge or final questionnaire and 
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participation in the study was terminated.  The PI gave all the participants who completed the 
study a $10 gift card to a local super market or super store at the time of their final data 
collection. 
 Study measures 
Demographics:  A demographic questionnaire was used to assess age, education, 
race/ethnicity, housing situation prior to admission, primary substance of abuse and mental 
health disorders prior to admission.  Medications being taken on admission and at 30 days were 
obtained from the medical record.   
Anxiety: Anxiety experienced over the past few days was measured using the Zung SAS. 
This 20 item self-administered anxiety scale is used for identifying somatic and psychological 
anxiety symptoms that have occurred within the past few days.  Each item is scored as a 4 point 
Likert scale with 5 items being reverse scored.  Anxiety scores between 45 and 60 are considered 
moderate anxiety, and scores between 60 and 74 are considered severe anxiety.  A raw score of > 
36 is clinically significant for difficulty carrying out normal work or activities (Zung, 1980). The 
Zung score (Zung, 1971) has good reliability (r = .71, alpha = .798) and content validity when 
compared to the Hamilton Anxiety scale (r =.75. Zung, 1971).  The Zung scale has been used in 
various populations for research and clinical assessment since its development in 1971 (Sharpley 
& Christie, 2007, Liao et al.2011).  
PTSD:  The PTSD Checklist—Civilian Version (PCL-C) was used to assess for 
symptoms of PTSD. This self-administered instrument has been in general use for more than 20 
years in both military and civilian populations (Orsillo, 2001). Scores of less than 29 are 
considered not significant for PTSD, while those above 45 are considered of high enough 
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severity for continuing with the assessment for the diagnosis of PTSD. The PCL consists of 17 
items identified with the diagnosis of PTSD in the DSM, and uses a 5 point Likert scale.  Internal 
consistency is high (r = .75) across studies in various populations (Wilkins, Lang & Norman, 
2011).  
Data Analysis 
        Descriptive statistics (e.g. mean, S.D., frequency and %) were calculated on demographic 
variables and included presence or absence of PTSD symptoms.  The key study variables of 
anxiety and treatment completion were also compared between the group who reported PTSD 
symptoms and the group who did not.  Research questions were answered using Pearson r 
correlation or t-test to identify differences in the anxiety scores between time periods. 
Results 
All 53 participants completed the baseline data collection.  Two participants (3.7%) left 
treatment within the first week, and an additional 3 (5.6%) left the second week.  At 30 days, a 
total of 13 (24.1%) were no longer in treatment.  Three were discharged after successful 
completion and 10 left without notice or were discharged due to drug use on property (18%). 
Only 3 were available to complete a final anxiety inventory at 90 days.  A total of 15(28.3%) 
participants dropped out of treatment prior to completion.  
Fifty-three participants completed baseline data and were between the ages of 18 and 63, 
with a majority (>70%) between ages 25-50 years.  The majority of participants self- identified 
as white, homeless or lived with friends, and were educated at the high school level or higher 
(see Table1).  Forty-nine percent (n=17) reported poly substance use with opiates and 38% (20) 
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were previously diagnosed with a mental health disorder.   High levels of anxiety were reported 
in 34% (n=18) of participants.  A score of >30 on the PCL was noted on 84% (n=48) of men and 
43% (n=23) reported PTSD symptoms in the high range (>50).   
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Table 5: Population demographics on admission 
 Male (n= 53 ) 
Age group [n (%)]  
    Less than 25 6 (11.3%) 
    26-35 14 (26.4%) 
    36-50 24 (45.3%) 
    Over 50 9 (17.1%) 
  
Race/Ethnicity [n (%)]  
    European/White 36 (67.9%) 
    Hispanic 12 (22.6%) 
    African American 2 (2.5%) 
  
Living situation prior to treatment [n(%)]  
    Family or self 15 (28.3%) 
    Living with parents 7 (13.2%) 
    Transitional housing or friends 8(15.1%) 
    Homeless 23 (43.4%) 
  
Years of Education   
    < High School 9 (17.0%) 
    GED 9 (17.0%) 
    HS Diploma 16 (30.2%) 
college/trade/AA 19(33.8%) 
   
Primary Substances of Abuse [n (%)]  
   Opiate  only 16 (13.2%) 
   Alcohol only  20 (37.7%) 
    Poly substance with opiate  17 (49%) 
  
Mental Health Disorders (pre admission) 20 (37.7%) 
  
Zung less than 37 -low anxiety [n (%)] 16 (30.2%) 
  
Zung greater than 50 – high Anxiety [n (%)]     18 (34.0%) 
PCL greater than 50 –High  [n (%)] 23 (43%) 
  
PCL greater than 40  Med (n (%)} 40 (75%) 
  
PCL greater than 30  Low [n (%)] 48 (84.2%) 
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Anxiety scores were consistent with empirical evidence which identifies a sharp decrease in 
anxiety by 30 days post detox with a general flattening of anxiety symptoms in the following 30 
days (Table 2).  The correlation between scores on admission and scores at 30 days (r = .59) and 
60 days (r = .64) was strong. 
 
Table 6: Anxiety scores at three time points 
  Admission     30 day    60 day    
                          
N =   53        39             21        
Mean (SD) 43.6(12.0)         34.5(8.7)        35.9(12.2) 
______________________________________________________________________________
        
 
The difference between anxiety level at admission and completing or leaving treatment 
early was not significant (p>.96).  There was a significant difference (t=2.36; p <02) between last 
anxiety score collected and leaving treatment early.  Participants who left treatment early 
reported higher anxiety. 
There was a positive correlation between endorsement of PTSD symptoms (PCL-C 
greater than 30) and endorsement of anxiety symptoms (Zung SAS) on admission (r = .49) 
Correlation was even greater with a PCL greater than 50 (r = .54).  While not significant, a trend 
in the slowing of the rate of anxiety diminishing in those with PTSD symptoms and those 
without (p >.08) was evident.  However, men with PTSD did not leave treatment prior to 
completion more frequently than those without PTSD.  
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Discussion 
Elevated anxiety symptoms in patients leaving treatment prior to completion of treatment 
was found to be more significant than the level of anxiety participants reported on admission to 
residential treatment following medical detox.  Anxiety associated with the common symptoms 
of alcohol and opiate withdrawal usually remits within 3-6 weeks (Brady, Haynes, Hartwell, & 
Killeen, 2013).  Hence there has been less interest in research treatment during this period 
although more than 25% of clients admitted to treatment drop out during this period.  Although 
patients with self-reported PTSD symptoms had a slightly slower rate of anxiety symptoms 
diminishing, it did not affect their length of time in treatment.  Whether the PTSD was childhood 
or adult onset, which may have been a variable, was not measured. 
Factors within an integrative program may also contribute to continued anxiety during 
residential treatment.  High social anxiety was identified as a predictor of early drop-out, 
especially in recovery programs, where much group work was expected (Lejuez, et al. 2008). 
Low distress tolerance (Daughters et al 2005) and high anxiety sensitivity (Lejuez, et al. 2008) 
may also contribute to sustained anxiety in a residential setting where task completion and group 
participation is expected.  The impact of PTSD and its association with substance abuse is well 
recognized. Gil-Rivas et al. (2009) noted that more than 45% of patients with PTSD in recovery 
relapsed within 3 months.  Therapy involving previous life trauma may increase anxiety (Kelly 
& Daley, 2013).  Individual trauma is often addressed in both individual therapy as well as in 
groups and is viewed as a necessary step in recovery treatment (Smith & Book, 2008).  An 
individual who has difficulty dealing with these thoughts and emotions may also have increased 
anxiety which could contribute to early dropout. 
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The presence and effect of other preexisting anxiety disorders must also be considered, 
and when recognized, treated (Kelly & Daley, 2013).  Almost 50% of patients with substance use 
disorders have self-reported generalized anxiety starting in late adolescence or earlier.  This is 
usually the rationale used for their addictive disorder, often described as self-medication (Darke, 
2013).  It is also well documented in history that alcohol and opiates have been used for 
millennia to reduce anxiety and associated stress symptoms and is the most effective coping 
mechanism these individuals have developed.  When anxiety becomes intolerable, persons with 
addictive disorders revert to behavior which brings relief (Brady, Haynes, Hartwell, & Killeen, 
2013).  This is relapse which was identified as the most common reason for participants leaving 
treatment early in this study.  Anxiety stemming from these underlying causes is much less likely 
to remit during the early weeks of recovery than anxiety associated with the common symptoms 
of alcohol and opiate withdrawal (Brady et al., 2013). 
This study addressed the symptoms of anxiety in early recovery.  Relief of anxiety during 
this period is critical for enhancing learning and building coping skills.  It is well recognized that 
the longer an individual stays in treatment, the better his chances of remaining in recovery 
(McLellan & McKay, 2003).  However in the present day managed-care environment, 30 days is 
usually the maximum allowed time for residential treatment.  This research study presents an 
argument for identifying and initiating treatment for underlying anxiety disorders early in the 
recovery process, as well as treating associated somatic complaints.  This will allow for 
maximum use of time in treatment to develop the internal tools and lifestyle changes needed to 
enhance potential for recovery.  
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Limitations 
This was a focused study of anxiety in men at a single residential recovery program.  
With the exception of PTSD symptoms, related variables were not considered.  These include 
depression which is highly correlated with anxiety but was not measured in this study, as well as 
a history of childhood trauma.  The psychotherapy method used by individual therapists or case 
managers was not identified, nor was the depth of the therapeutic relationship, both of which 
could have impacted level of anxiety.  The study was underpowered and limited to individuals 
with primary alcohol or opiate use disorders.  However, many were poly-substance abusers and 
also may have had other medical or mood disorders which could have affected outcomes in a 
larger study.  Of interest, most participants who left the residential program early were 
unavailable to complete follow up anxiety scales and were unwilling to complete questionnaires 
prior to leaving.  Contact phone numbers had often been disconnected or the individual 
answering the phone was unaware of the participant’s whereabouts.  Anecdotally, many of the 
participants returned to detox in the following months and related their stories regarding relapse. 
Conclusion 
Anxiety is a significant factor in relapse during the first months of substance abuse 
recovery.  Individuals with persistent anxiety are less likely to complete treatment than those 
whose anxiety remits during the first few days or weeks after detox.   Post-Traumatic Stress 
Disorder is a significant variable in substance abuse and in this study it appears that it may 
influence the course of anxiety symptom degradation. 
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Recommendations 
More research is needed to identify methods of decreasing and sustaining decreases in 
anxiety very early in recovery in order to enhance program retention and ultimately maintain 
substance abuse recovery.  There is a need for more study on the integration of psychotherapy 
such as motivational interviewing and non-sedating pharmacotherapy such as long acting 
naltrexone as a means to decrease anxiety during the initial weeks of treatment.  This is the time 
when anxiety peaks and dropout from treatment is most likely.  Early interventions are critical 
for enhancing learning and sustaining desire for recovery through decreasing anxiety symptoms 
and so enabling the substance abuser to apply the adaptive behaviors learned in therapy to their 
own lives.  Complementary and alternative medications/treatments (CAM), as well as somatic 
therapies now being researched, may also have a role in decreasing anxiety without the sedating 
effect often seen with psychopharmacotherapy.  Individualized treatment should also include 
genetic testing for identifying sensitivities to medications.  This would assist in prescribing the 
most likely effective pharmacotherapy for the individual early in treatment. 
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University of Central Florida Institutional Review Board 
Office of Research & Commercialization 
12201 Research Parkway, Suite 501 
Orlando, Florida 32826-3246 
Telephone: 407-823-2901 or 407-882-2276 
www.research.ucf.edu/compliance/irb.html 
 
Approval of Human Research 
 
From: UCF Institutional Review Board #1 FWA00000351, IRB00001138 
 
To: Janet M. Hutchison 
 
Date: June 20, 2013 
 
Dear Researcher: 
On6/20/2013 the IRB approved the following human participant research until 5/21/2014 inclusive: 
Type of Review: Submission Correction for UCF Initial Review Submission Form 
Full Board Review 
Project Title:  Using Cranial Electrotherapy Stimulation to Decrease Anxiety 
Symptoms following Opiate and Alcohol Withdrawal 
Investigator: Janet M. 
Hutchison IRB Number: SBE-13-
09325 
Funding Agency:  Electromedical Products International, Inc | 2201 Garrett Morris 
Parkway | Mineral Wells | TX | 76067( EPI ), International 
Nurses Society on Addictions( INTnsa ) 
Grant Title:
 N/
A Research ID:
 N/
A 
 
The scientific merit of the research was considered during the IRB review. The Continuing Review 
Application must be submitted 30days prior to the expiration date for studies that were previously  
expedited, and 60 days prior to the expiration date for research that was previously reviewed at a convened 
meeting. Do not make changes to the study (i.e., protocol, methodology, consent form, personnel, site,   
etc.) before obtaining IRB approval.  A Modification Form cannot be used to extend the approval period of 
a study.   All forms may be completed and submitted online at https://iris.research.ucf.edu . 
 
If continuing review approval is not granted before the expiration date of 5/21/2014, 
approval of this research expires on that date. When you have completed your research, please submit a 
Study Closure request in iRIS so that IRB records will be accurate. 
 
Use of the approved, stamped consent document(s) is required.  The new form supersedes all previous 
versions, which are now invalid for further use.  Only approved investigators (or other approved key study 
personnel) may solicit consent for research participation.  Participants or their representatives must receive 
a signed and dated copy of the consent form(s). 
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In the conduct of this research, you are responsible to follow the requirements of the Investigator Manual. 
On behalf of Sophia Dziegielewski, Ph.D., L.C.S.W., UCF IRB Chair, this letter is signed by: 
Signature applied by Patria Davis  on 06/20/2013 11:32:58 AM EDT 
 
IRB Coordinator 
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Self-Administered State-Trait Anxiety Inventory (STAI-6)* 
 
Study Number  _______      Date _ ____ 
 
 A number of statements that people have used to describe themselves are given below. 
Read each statement and then circle the most appropriate number to the right of the statement to 
indicate how you feel right now, at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement but give the answer that seems to describe your  
present feelings best. 
 
 Not at all Somewhat Moderately Very much 
1. I feel calm 1 2 3 4 
2. I am tense 1 2 3 4 
3. I feel upset 1 2 3 4 
4. I am relaxed 1 2 3 4 
5. I feel content 1 2 3 4 
6. I am worried 1 2 3 4 
 
Please make sure that you have answered all the questions. 
 
Note. * Adapted from “The development of a six-item short-form of the state scale of the 
Spielberger State-Trait Anxiety Inventory (STAI),” by T. M. Marteau and H. Bekker, 1992, 
British Journal of Clinical Psychology, 31, p. 306. Copyright 1992 by the British Psychological 
Society. Reprinted with permission.   
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